Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Generic Package Inserts Need Improvement: Forum
May 26, 2003
- BUSINESS NEWS IN BRIEF
May 26, 2003
- MEDICAL FACILITIES & NURSING CARE NES IN BRIEF
May 26, 2003
- Website News
May 26, 2003
- Innovative Medical Care Procedures Should Be Patent-protected: METI
May 26, 2003
- Annual Business Results
May 26, 2003
- Fewer Children for 22nd Year in a Row: Somusho Statistics
May 26, 2003
- Annual Business Results
May 26, 2003
- REGULATORY NEWS IN BRIEF
May 26, 2003
- Annual Business Results
May 26, 2003
- 50th Anniversary of DNA Discovery Celebrated
May 26, 2003
- Shoda Appointed President of Sankyo
May 26, 2003
- Annual Business Results
May 26, 2003
- RESEARCH &DEVELOPMENT NEWS IN BRIEF
May 26, 2003
- BULLETIN
May 26, 2003
- Annual Business Results
May 26, 2003
- OTC NEWS IN BRIEF
May 26, 2003
- Tanabe Calls For Sales of \192.0 Billion in New 3-Year Plan
May 26, 2003
- Annual Business Results
May 26, 2003
- MEDICAL DEVICE NEWS IN BRIEF
May 26, 2003
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…